Navigation Links
ADVENTRX Reviews Data Supporting Development Of ANX-188 In New Indications
Date:2/26/2013

adhesive interactions and providing time for natural repair mechanisms to restore normal functioning.  Meanwhile, because pathological hydrophobic domains are not characteristically present in a healthy circulation, ANX-188 has no clinically significant activity in healthy circulatory tissue.  While this mechanism specifically targets hydrophobic domains, these domains can be widespread in sick or injured patients.  This 'broadly targeted' activity gives ANX-188 potential to address multiple pathophysiological processes in complex indications relative to drugs based on specific receptor/ligand interactions." 

Santosh Vetticaden, Chief Medical Officer, said: "Proof-of-concept in experimental models has been demonstrated with the active ingredient in ANX-188 in a wide range of diseases, such as arterial disease, stroke, shock and heart failure.  As we advance ANX-188 into new indications, we intend to leverage already completed IND-enabling toxicology studies, phase 1 safety studies and the other activities that consume so much time and money in drug development.  With clinical trial material already in-hand, we expect to move ANX-188 directly into phase 2 studies and generate clinical proof-of-concept data in new indications in relatively short time frames with relatively modest investment." 

About the MAST (Molecular Adhesion and Sealant Technology) Platform

The MAST platform reflects the repository of both proprietary (to ADVENTRX) and non-proprietary poloxamer-related data, know-how and other information that has been developed over the course of several decades by numerous sponsors, most recently by ADVENTRX.  It reflects the accumulated knowledge of over 100 pharmacology studies, more than 15 clinical studies in multiple indications in which over 2,500 subjects have been exposed to both purified and non-purified poloxamer 188, and over two decades of experience manufacturing and purifying poloxamers
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. ADVENTRX To Present At The Cowen And Company 33rd Annual Health Care Conference On March 4
2. ADVENTRX To Present At The 15th Annual BIO CEO & Investor Conference On February 12
3. ADVENTRX Initiates Pivotal Phase 3 Study of ANX-188
4. ADVENTRX Reports Third Quarter 2012 Financial Results
5. ADVENTRX Announces Details Of The Phase 3 Study Of ANX-188
6. ADVENTRX Announces Appointment Of Ted W. Love M.D. To Board Of Directors
7. ADVENTRX Pharmaceuticals To Present At The Rodman & Renshaw Annual Global Investment Conference On September 10
8. ADVENTRX Announces Appointment Of Chief Medical Officer
9. ADVENTRX Pharmaceuticals to Present at 1st Annual Sickle Cell Disease Therapeutics Conference
10. ADVENTRX Applauds Inclusion of Rare Diseases Provisions in the FDA Safety and Innovation Act
11. ADVENTRX Pharmaceuticals To Present At The OneMedForum New York 2012 Emerging Company Finance Conference On July 12
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... IRVING, Texas , Jan. 15, 2014  Novation, the ... company, awarded several new IT value-added reseller (VAR) national ... with IT goods and services at lower costs. These ... value-added services such as initiative assistance and ongoing IT ...
(Date:1/15/2014)... 15, 2014 Massachusetts General Hospital (MGH), the ... ) announced today that they have launched a ... therapeutic targets and develop novel therapies for inflammatory ... millions worldwide. The MGH-Broad-Amgen collaboration brings together scientists ...
(Date:1/15/2014)... Jan. 15, 2014  Humberto C. Antunes,  Galderma  worldwide CEO, ... the Journal of Drugs in Dermatology (JDD) ... (ODAC). The event is January 17-20, 2014, at the Omni Orlando ... The ODAC is a distinguished event ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
... CHADDS FORD, Pa. , Jan. 19 ... partners, Teikoku Seiyaku Co., Ltd. and Teikoku Pharma USA, Inc. ... Inc. advising of the filing of an Abbreviated New Drug ... (lidocaine topical patch 5%). , The company is currently reviewing ...
... Partners Forge Collaboration to Fund Discovery of New Drugs that Target the ... MILAN, Italy , Jan. 19 Fast Forward, LLC ... Sclerosis Society, and the Juvenile Diabetes Research Foundation (JDRF) , ... diabetes in the world today announced a collaborative partnership with Axxam SpA ...
Cached Medicine Technology:Endo Pharmaceuticals Announces Receipt of Paragraph IV Certification 2Endo Pharmaceuticals Announces Receipt of Paragraph IV Certification 3Endo Pharmaceuticals Announces Receipt of Paragraph IV Certification 4Endo Pharmaceuticals Announces Receipt of Paragraph IV Certification 5Fast Forward, Juvenile Diabetes Research Foundation and Axxam SpA Join Forces to Accelerate Development of Treatments for Multiple Sclerosis and Type 1 Diabetes 2Fast Forward, Juvenile Diabetes Research Foundation and Axxam SpA Join Forces to Accelerate Development of Treatments for Multiple Sclerosis and Type 1 Diabetes 3Fast Forward, Juvenile Diabetes Research Foundation and Axxam SpA Join Forces to Accelerate Development of Treatments for Multiple Sclerosis and Type 1 Diabetes 4Fast Forward, Juvenile Diabetes Research Foundation and Axxam SpA Join Forces to Accelerate Development of Treatments for Multiple Sclerosis and Type 1 Diabetes 5
(Date:4/22/2014)... Association for Molecular Pathology (AMP) released a report ... on recommendations for a molecular diagnostics curriculum ... education. The report was prepared by the Medical ... AMP Training and Education Committee. "Our goal was ... medical laboratory scientists appropriately in order to manage ...
(Date:4/22/2014)... the standard measurement for assessing glycemic control over time ... typically measured every few months in a laboratory, but ... estimates A1c using self-monitored blood glucose (SMBG) readings, as ... DTT ), a peer-reviewed journal from Mary Ann Liebert, ... DTT website at http://www.liebertpub.com/dtt . , ...
(Date:4/22/2014)... To help rein in massive health care spending, a ... urgently find ways to incentivize pharmaceutical companies and device ... Instead of examining existing medical technologies and their use, ... affect what drugs and medical devices get created in ... health care spending with as little loss of health ...
(Date:4/22/2014)... ARBOR, Mich. Nearly 7 in 10 Americans ... a new national survey by researchers at the University ... with children under the age of 18 at home, ... more likely than other adults to support universal coverage ... appear in the Journal of the American Medical ...
(Date:4/22/2014)... news release is available in German . ... Perutz Laboratories of the University of Vienna and the Medical ... have now shown how double stranded RNA, such as viral ... cell. During the immune response against viral infection, the protein ... There it modifies viral RNA to inhibit reproduction of the ...
Breaking Medicine News(10 mins):Health News:AMP publishes curriculum recommendations for medical laboratory scientists 2Health News:US medical innovation needs smarter incentives to cut health spending, study finds 2Health News:US medical innovation needs smarter incentives to cut health spending, study finds 3Health News:More than two-thirds of Americans support mandated coverage of birth control in health plans 2Health News:How the body fights against viruses 2Health News:How the body fights against viruses 3
... The Reeve Foundation debuts new national ad campaign giving ... HILLS, N.J., Nov. 3 The Christopher & Dana ... advertising,campaign. The campaign presents an edgier side of the ... life is like through the eyes of,someone living with ...
... critical need to review current treatment strategies for the ... to a series of international papers in the November ... with severe disability, unmet treatment need and little clinical ... Professor David W Dodick from the Mayo Clinic College ...
... 3 Pregis Corporation, a leading,international manufacturer, ... specialty packaging solutions, will conduct an investor,conference ... results on Friday,November 14, 2008 at 10:00 ... 617-614-4909; Participant Passcode: 68623125. A replay of,the ...
... crucial element in hip,fracture recovery, ROSEMONT, Ill., ... fracture are referred to their primary care physicians ... published in the,November 2008 issue of The Journal ... an osteoporosis management program initiated by an,orthopaedic surgeon ...
... LifeNet Health,a leading allograft bio-implant company, ... United States Food and Drug Administration (FDA) ... technology., LifeNet Health received clearance for ... donor cells from cardiovascular tissues,while retaining the ...
... (Nasdaq: BMRN ) announced today the initiation ... with the lysosomal storage disease,Mucopolysaccharidosis Type IVA (MPS ... augment available data on the disease by measuring ... patients.,BioMarin expects to follow the MorCAP program with ...
Cached Medicine News:Health News:Christopher & Dana Reeve Foundation Launches First-Ever National Advertising Campaign 2Health News:Urgent need for research into the best treatment for medication overuse headaches 2Health News:Urgent need for research into the best treatment for medication overuse headaches 3Health News:Urgent need for research into the best treatment for medication overuse headaches 4Health News:Treating Osteoporosis After Hip Fracture 2Health News:Treating Osteoporosis After Hip Fracture 3Health News:BioMarin Announces Initiation of Clinical Assessment Program for Morquio A Syndrome 2Health News:BioMarin Announces Initiation of Clinical Assessment Program for Morquio A Syndrome 3Health News:BioMarin Announces Initiation of Clinical Assessment Program for Morquio A Syndrome 4
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: